Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Boostrix-ex-US

Phase 2Biologic

Boostrix-ex-US is one of 20 biologic programs targeting Diphtheria. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

19

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiphtheriaActive, not recruiting

DiphtheriaPhase 2

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Diphtheria

#DrugCompanyPhaseTrials

Comparator: Pbo

Rotarix ™

Menactra

GSK 257049

Infanrix

Havrix

Rsvpref3 Vaccine

Acthib

REVAXIS

Vi-Polysaccharide Vaccine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diphtheria1 trial

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

Completed· GSK logo

GSK·Phase 2·NCT04138056·509 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Boostrix-ex-US. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Boostrix-ex-US compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Boostrix-ex-US. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: GSK

Related News